 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12 |
- [VIRTUAL] Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2095;
P1/2
Funding: F. Hoffmann-La Roche, Ltd. Clinical trial identification: NCT03337698.
- || ciforadenant (CPI-444) / Corvus Pharma
Clinical, Journal: Lessons from the A2A Adenosine Receptor Antagonist-Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer. (Pubmed Central) - Jul 9, 2020
In this issue of Cancer Discovery, Fong and colleagues describe the encouraging observations of tumor regression, disease control, and survival of patients with otherwise refractory renal cell cancer with progressive disease after treatment with the conceptually novel oral antagonist of the A2A adenosine receptor (A2AR), ciforadenant. A2AR antagonists may represent the until now missing but critically important part of more effective immunotherapies of cancer, because they prevent the inhibition of tumor-reactive T and natural killer cells by blocking the immunosuppressive hypoxia-A2A-adenosinergic signaling, which represents an emerging immunosuppressive hallmark of tumors that are the most resistant to therapies.See related article by Fong et al., p. 40.
- || mupadolimab (CPI-006) / Corvus Pharma
New P1 trial: Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients (clinicaltrials.gov) - Jul 8, 2020
P1, N=30, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
- ciforadenant (CPI-444) / Corvus Pharma
[VIRTUAL] CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC). (Poster Board 94) - Apr 29, 2020 - Abstract #ASCO2020ASCO_986;
P1
Enumerating tumor infiltrating CD68+ cells may be a valuable biomarker for identifying pts that will respond to adenosine blockade. Research Funding: Corvus Pharmaceuticals
- || ciforadenant (CPI-444) / Corvus Pharma
New P1 trial, Combination therapy: Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2020
P1b, N=28, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
- || Tecentriq (atezolizumab) / Roche, ciforadenant (CPI-444) / Corvus Pharma
$CRVS off 17%. Ciforadenant in ~4L mCRPC (some given Tecentriq combo): 1/35 PR #GU20 (Twitter) - Feb 13, 2020
- |||||| Tecentriq (atezolizumab) / Roche, ciforadenant (CPI-444) / Corvus Pharma
📅 Thursday Poster Session @ASCO #GU20 📝 Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced mCRPC @LaurenCHarshman ✴️ mCRPC can be sensitive to A2AR blockade with ciforadenant https://t.co/hGJuKwP5IA #oncoalert (Twitter) - Feb 12, 2020
- Tecentriq (atezolizumab) / Roche, ciforadenant (CPI-444) / Corvus Pharma
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC). (Poster Board F9) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_592;
P1
Cytokine changes provide evidence of treatment-induced inflammatory response, which may predict efficacy. Data on all 33 enrolled pts will be presented.
- Tecentriq (atezolizumab) / Roche, ciforadenant (CPI-444) / Corvus Pharma
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC). (Poster Board F9) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_289;
P1
Cytokine changes provide evidence of treatment-induced inflammatory response, which may predict efficacy. Data on all 33 enrolled pts will be presented.
- |||||| CPI-006 / Corvus Pharma
Clinical: CPI-006, an anti-CD73 Ab, has potent immunomodulatory activity in early phase trials, with some striking anti-tumor responses in some CBI resistant RCC/prostate Ca patients, reports @jasonlukemd of @UPMCHillmanCC #SITC2019 #SITC19 (Twitter) - Nov 8, 2019
- ||||| CPI-006 / Corvus Pharma
@jasonlukemd presents anti-CD73 (CPI-006) data. Early data but interesting combination trial design and data to date. #SITC2019 (Twitter) - Nov 8, 2019
- |||||| CPI-006 / Corvus Pharma
Clinical: Dr. Jason Luke previews his session for #SITC19, "Immunobiology and Clinical Activity of CPI-006." Join @jasonlukemd from 2-4:20 pm tomorrow to learn more about the innovation from @UPMCHillmanCC. See other presenters from UPMC at @sitcancer this week: https://t.co/C6nzF6T1Pd (Twitter) - Nov 7, 2019
- CPI-818 / Corvus Pharma
A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5764;
P1
Study Status: This study is currently enrolling . US NIH Clinical Trials Registration Number NCT03952078.
- CPI-818 / Corvus Pharma
Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2403;
P1
Preliminary data from a phase 1/1b study shows CPI-818 at 100 mg BID was tolerable with acceptable bioavailability and ITK occupancy . Further dose escalation is ongoing.
- A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_795;
P1
Further dose escalation is ongoing. N/A
- CPI-006 / Corvus Pharma, Tecentriq (atezolizumab) / Roche, ciforadenant (CPI-444) / Corvus Pharma
ADENOSINE AND AMP GENE EXPRESSION PROFILES PREDICT RESPONSE TO ADENOSINE PATHWAY THERAPIES AND INDICATE A NEED FOR DUAL BLOCKADE OF CD73 AND A2AR WITH CD73 INHIBITORS. (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_489;
P1
These GEPs may be used as biomarkers for patient selection. CD73 antagonists alone may be limited by the induction of compensatory immunosuppressive pathways mediated by AMP accumulation.
- CPI-006 / Corvus Pharma
Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers (Potomac Ballroom) - Oct 2, 2019 - Abstract #SITC2019SITC_325;
P1
Activation markers and changes in circulating lymphocytes are consistent with trafficking to nodal sites and sensitization of T and B cells. Preliminary evidence of anti-tumor activity has been observed without enrichment for tumor CD73 expression or adenosine gene signature.
- | ciforadenant (CPI-444) / Corvus Pharma
Preclinical, Journal, PD(L)-1 Biomarker, IO Biomarker: A2AR Antagonism with CPI-444 Induces Anti-Tumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models. (Pubmed Central) - Aug 30, 2019
The antitumor efficacy of CPI-444 with and without anti-PD-L1 was associated with increased T-cell activation, a compensatory increase in CD73 expression, and induction of a Th1 gene expression signature consistent with immune activation. These results suggest a broad role for adenosine-mediated immunosuppression in tumors and justify the further evaluation of CPI-444 as a therapeutic agent in patients with solid tumors.
- | Enrollment change, Metastases: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Jul 11, 2019
P1/2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
These results suggest a broad role for adenosine-mediated immunosuppression in tumors and justify the further evaluation of CPI-444 as a therapeutic agent in patients with solid tumors. N=410 --> 250
- ||| CPI-006 / Corvus Pharma
Anti-CD73 and CPI-006 (Twitter) - Jun 3, 2019
- ||||| CPI-006 / Corvus Pharma
Happening now @UPMCHillmanCC immunologist, Dr. Jason Luke (@jasonlukemd) presents early trial success with CPI-006 #Immunotherapy for advanced cancers. @UPMCNews #ASCO2019 (Twitter) - Jun 2, 2019
- ||||| CPI-006 / Corvus Pharma
P1 data: Great phase 1 data of CPI-006 presented by @jasonlukemd #ASCO19 (Twitter) - Jun 2, 2019
- ||| soquelitinib (CPI-818) / Corvus Pharma
New P1 trial: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (clinicaltrials.gov) - May 15, 2019
P1, N=151, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
- ||| Enrollment change, Metastases: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Mar 1, 2019
P1/2, N=410, Recruiting, Sponsor: Hoffmann-La Roche
N=410 --> 250 N=292 --> 410
- | ciforadenant (CPI-444) / Corvus Pharma
Enrollment change, Combination therapy, Metastases: Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers (clinicaltrials.gov) - Sep 12, 2018
P1, N=323, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
N=292 --> 410 N=534 --> 323
- | ciforadenant (CPI-444) / Corvus Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers (clinicaltrials.gov) - Jul 30, 2018
P1, N=534, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
N=534 --> 323 Trial completion date: Dec 2018 --> Oct 2021 | Trial primary completion date: Jun 2018 --> Jun 2021
- ||| mupadolimab (CPI-006) / Corvus Pharma, ciforadenant (CPI-444) / Corvus Pharma
Enrollment open, Combination therapy, Metastases: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov) - Mar 29, 2018
P1, N=378, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
Trial completion date: Dec 2018 --> Oct 2021 | Trial primary completion date: Jun 2018 --> Jun 2021 Not yet recruiting --> Recruiting
- ||| mupadolimab (CPI-006) / Corvus Pharma, ciforadenant (CPI-444) / Corvus Pharma
New P1 trial, Combination therapy, Metastases: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov) - Mar 6, 2018
P1, N=378, Not yet recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
- |||| Enrollment open, Metastases: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Nov 17, 2017
P1/2, N=307, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| New P1/2 trial, Metastases: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Nov 9, 2017
P1/2, N=307, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| ciforadenant (CPI-444) / Corvus Pharma
Enrollment open, Combination therapy, Metastases: Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers (clinicaltrials.gov) - Feb 12, 2016
P1, N=534, Recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| ciforadenant (CPI-444) / Corvus Pharma
New P1 trial, Combination therapy, Metastases: Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers (clinicaltrials.gov) - Jan 14, 2016
P1, N=534, Not yet recruiting, Sponsor: Corvus Pharmaceuticals, Inc.
- | ciforadenant (CPI-444) / Corvus Pharma
New P1/2 trial: Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=31, Completed, Sponsor: Vernalis (R&D) Ltd
- | ciforadenant (CPI-444) / Corvus Pharma
New P1 trial, Adverse events: A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men (clinicaltrials.gov) - Jul 4, 2012
P1, N=49, Completed, Sponsor: Vernalis (R&D) Ltd